Matteo Pelosini

Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life

Gheath Alatrash, Marcos de Lima, Nelson Hamerschlak et al. · Biology of Blood and Marrow Transplantation · 2011 · 93 citations · Full text

Mixed-phenotype Acute Leukemia, Pharmacotherapy, Myeloid Neoplasia +18

Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy

Marco Tuccori, Daniele Focosi, Corrado Blandizzi et al. · The Oncologist · 2010 · 55 citations · Full text

Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial

Muzaffar H. Qazilbash, Rima M. Saliba, Yago Nieto et al. · Biology of Blood and Marrow Transplantation · 2008 · 43 citations · Full text

Immunology, Immunotherapy, High-dose Melphalan +17

Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma

Yvonne A. Efebera, Sofia R. Qureshi, Suzanne Cole et al. · Biology of Blood and Marrow Transplantation · 2010 · 37 citations

Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients

Susanna Grassi, Francesca Guerrini, Elena Ciabatti et al. · Cancers · 2020 · 34 citations · Full text

Engineering, Mixed-phenotype Acute Leukemia, Genetics +19